Abstract

Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.


Claims
Download PDF
Document Preview
Document History
  • Publication: Sep 18, 2018
  • Application: Aug 20, 2014
    US US 201414464536 A
  • Priority: Aug 20, 2014
    US US 201414464536 A
  • Priority: Oct 20, 2005
    US US 25561705 A
  • Priority: Oct 20, 2004
    US US 62045204 P

Download Citation


Sign in to the Lens

Feedback